TO THE EDITOR
Approximately 15% of patients with acute lymphoblastic leukemia (ALL) are 10-20 years old at diagnosis. Adolescents with ALL who are 15 years of age or older are treated by pediatricians or hematologists, depending on their referral. The treatment of adolescent patients according to pediatric or adult protocols results in relatively small numbers of this age group in clinical trials. Consequently, limited information about patient characteristics and survival rates of adolescents over 15 years of age is available.
In the Netherlands, adolescent patients with ALL are treated according to pediatric Dutch Childhood Oncology Group (DCOG) or adult Dutch-Belgian Hemato-Oncology Cooperative Study Group (HOVON) treatment protocols, depending on their referral. We retrospectively compared the treatment results and reviewed treatment strategies of 47 adolescents (15-18 years of age) treated according to DCOG protocols (DCOG ALL 6-9) and 44 15-18-year-old adolescents and 29 19-20-year-old adolescents treated according HOVON protocols (HOVON ALL-5 and HOVON ALL-18).
Adolescents treated on the pediatric DCOG protocols had approximately a 35% higher probability of survival at 5 years compared to those treated on the adult HOVON protocols (Table 2 and Figure 1 ). For 15-18-year-old adolescents, the 5-years event-free survival (EFS) when treated on pediatric protocols was 69%, which is significantly higher than when treated on adult protocols (34%; P ¼ 0.0001). The difference in survival is due to both a significantly lower relapse rate as well as a lower toxic death rate in the DCOG trials compared to the HOVON trials. Of the 46 patients of DCOG who achieved complete remission (CR), 12 patients relapsed (26%), whereas of the 15-18-year-old HOVON patients achieving CR, 22 out of 40 patients (55%) relapsed. At 5 years, only 4% of the DCOG patients had died from treatment related toxicity, whereas 24% of the HOVON patients had experienced treatment-related death. Almost half of the nonleukemic deaths in the HOVON groups did not result from toxicity caused by the initial protocol, but was related to relapse treatment.
Our results are comparable to other studies analyzing the outcome of adolescents treated on pediatric or adult protocols. Adolescents treated on the pediatric CCG (Children Cancer Group; US) and FRALLE (France) protocols had EFS rates (64 and 67% respectively) being 26% higher than that of the adolescents treated on the adult CALGB (US) and LALA (France) trials (38 and 41%, respectively) 1 (Stock et al. Blood 2000; 96: 467a; abstract). In accordance with these studies, patient characteristics of the adolescents treated on the pediatric DCOG and adult HOVON protocols in our study were comparable, except for a small difference in mean age (Table 1) . It is very unlikely that the difference of 1.5 years in mean age can cause the 35% survival difference. This is illustrated by the fact that the outcome of the 19-20-year-old adolescents in HOVON trials did not differ from that of the 15-18-year-old adolescents in HOVON trials (Table 2 and Figure 1 ).
The differences in outcome may be explained by differences between DCOG and HOVON treatment strategies, outlined in Figure 2 . Several treatment elements present in the DCOG protocols were absent in the HOVON protocols. DCOG treatment strategies generally consisted of induction therapy, followed by high-dose methotrexate, reinduction/intensification courses and maintenance therapy, whereas HOVON strategies focused on intensified chemotherapy relatively often followed by bone marrow transplantation (BMT).
The first difference between the pediatric DCOG and adult HOVON treatment strategies was the absence of methotrexate in the HOVON protocols, whereas the cumulative dosage of methotrexate in the DCOG protocols was 14.3 g/m 2 . Methotrexate, usually combined with intensive intrathecal therapy, has shown to provide adequate prevention of CNS relapses. It also decreases hematological and testicular relapses, resulting in improved survival rates. 2 Secondly, reinduction/intensification therapy was given to patients treated according to DCOG ALL9 HR, ALL8 and ALL7 (after September 1990), whereas none of the HOVON patients received this kind of treatment. A meta-analysis performed by Richards et al 3 demonstrated that both early and delayed reinduction/intensification resulted in a 10-15% improvement of event-free survival in ALL. Additional DCOG data illustrating the importance of reinduction/intensification courses: in our study, 3/29 (10%) DCOG adolescents treated with reinduction vs 9/18 (50%) DCOG adolescents treated without reinduction relapsed. These data show that adolescents should receive intensification/reinduction therapy.
Thirdly, pediatric DCOG protocols included maintenance therapy in contrast to adult HOVON protocols. Attempts to omit or shorten maintenance therapy to a total therapy duration o2 years from pediatric ALL regimens have resulted in inferior outcome. 3, 4 The absence of maintenance resulted in a very low cumulative dosage (HOVON ALL-18: 1.7 g/m 2 ) or absence (HOVON ALL-5) of the antimetabolite 6-mercaptopurine in the HOVON protocols, whereas the mean cumulative dosage of 6-mercaptopurine was 25.5 g/m 2 in the DCOG protocols. The absence of 6-mercaptopurine might have contributed to the high relapse rate of adolescents treated on HOVON protocols, as an inverse correlation between cumulative dosage of 6-mercaptopurine and relapse rate has been documented. 5 A fourth difference was that HOVON protocols consisted of intensified chemotherapy followed by BMT, whereas BMT was only applied in small subsets of DCOG patients at very high risk for relapse (t(9;22), MLL rearrangements and slow response to induction). Only 4% of the DCOG patients received an allogeneic transplantation in first CR, whereas 25% of the HOVON patients received an allogeneic transplantation in first CR (17 HLA identical, two matched unrelated donor) and 30% of the HOVON patients were autotransplanted in first CR. As 5/9 HOVON adolescents died in first CR after they underwent allogeneic BMT, toxicity of allogeneic BMT might have contributed to the high treatmentrelated mortality in the HOVON trials. In childhood ALL, the benefit of allogeneic BMT has only proven to outweigh its risk of toxic death in Philadelphia-positive ALL. 6 At present, allogeneic BMT in first CR should therefore only be confined to very high-risk patients. Addition of autologous BMT to chemotherapy (HOVON ALL-18) did not result in improvement of relapse rates, as the percentage of relapse of patients being treated with chemotherapy followed by autologous BMT was similar (approximately 50%) to patients receiving chemotherapy alone. In other studies, autologous BMT has also not proven to be of additional benefit to chemotherapy in ALL patients. 7 The fifth important difference between DCOG and HOVON was the time interval between courses. The intervals in the pediatric DCOG protocols were short (maximum of 1 week interval between courses), whereas intervals up to 4 weeks were permitted in the HOVON ALL-5 protocol. In contrast to the treatment of patients with acute myeloid leukemia, continuous administration of cytostatic drugs at maximal dose intensity seems to be of great importance in ALL treatment. This is illustrated by the treatment results of adolescents treated according to HOVON ALL-5 and HOVON ALL-18 in our study. Patients treated on the HOVON-5 protocol, an AML-based treatment strategy allowing relatively long recovery intervals Incidence of cytogenetic abnormalities is restricted to patients from whom cytogenetics was available. NOS ¼ not otherwise specified. **Po0.01. showed a trend for a lower CR rate (86 vs 93%; P ¼ 0.43), a lower 5-year EFS (24 vs 41%; P ¼ 0.24), a higher 5-year relapse rate (68 vs 44%; P ¼ 0.21) and a higher incidence of treatmentrelated mortality (28 vs 21%; P ¼ 0.30) than adolescents treated on the HOVON-18 ALL protocol. Although the outcome of adolescents treated according to HOVON ALL-18 was better than when treated according to HOVON ALL-5, the difference in treatment results of adolescents treated on the DCOG protocols and those treated according to the HOVON ALL-18 protocol remained highly significant. Table 2 ). Methotrexate it.
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Figure 2
Overview of DCOG and HOVON treatment protocols.
Correspondence
Finally, the cumulative dosages of cytostatic drugs differed between DCOG and HOVON protocols. Besides the absence of 6-mercaptopurine and methotrexate in HOVON protocols, other drugs such as dexamethasone, L-asparaginase and vincristine were given in higher cumulative dosages in the DCOG compared to the HOVON protocols. In the HOVON-5 ALL study, a relatively high cumulative dosage of cytarabine was given (24.0 g/m 2 ), comparable to therapy protocols designed for patients with acute myeloid leukemia. Regarding the type of administered corticosteroids, dexamethasone (mean cumulative dosage: 1.0 g/m 2 ) was predominantly prescribed in the DCOG protocols, whereas in HOVON protocols only prednisone (mean cumulative dosage: 1.8 g/m 2 ) was given. Dexamethasone provides better prophylaxis of CNS relapses than prednisone and a recent CCG study observed fewer isolated bone marrow relapses when dexamethasone instead of prednisone was given. 8 Both a higher effective amount of corticosteroids as the more favorable antileukemic characteristics of dexamethasone compared to prednisone may have contributed to the better outcome of adolescents treated on DCOG protocols compared to HOVON protocols.
Adolescents in the DCOG studies generally received more Lasparaginase than the adolescents in the HOVON studies (mean cumulative dosages: 101 000 and 70 000 U/m 2 , respectively). The importance of L-asparaginase for ALL treatment has long been recognized. Recent studies have demonstrated that intensification of L-asparaginase therapy results in improved survival rates, despite increased toxicity. 9 The amount of vincristine given to the DCOG adolescents was high compared to the amount of vincristine given to HOVON adolescents (mean cumulative dosages: 48.0 and 6.8 mg/m 2 , respectively). No randomized trials have been described evaluating the influence of the amount or dosage of vincristine, but addition of vincristine and corticosteroids to antimetabolite maintenance therapy has been demonstrated to improve outcome. 3 Less compliance with treatment of adolescents and adults compared to children and their parents has also been suggested to be of influence on outcome. However, as almost all cytostatic drugs were given intravenously in the HOVON protocols, it is unlikely that compliance might have negatively influenced the outcome of the adolescents treated on HOVON protocols in the present study.
It is difficult to draw any definite conclusions about which of these above-mentioned therapy differences has had the highest influence on the differences in survival between adolescents treated according to DCOG and HOVON protocols. The results of our study will lead to adjustment of treatment strategies for adolescents and young adults with ALL in the Netherlands. As it is likely that patients over the age of 20 years can also benefit from pediatric approaches, treatment strategies might also be adapted for adults with ALL. Toxicity will not be a problem in the adolescent age group, as adolescents treated according to the DCOG regimen in the present study tolerated therapy very well. However, the upper age limit of 'a pediatric approach' is difficult to define, as increased cellular drug resistance (corticosteroids, L-asparaginase, cytarabine, daunorubicin and vincristine), differences in the metabolism of antimetabolites and decreased drug tolerance (L-asparaginase) with increasing age can result in lower cure rates and more side effects in older ALL patients. Collaboration between hematooncologists treating children and adults must result in new protocol designs based on experience from pediatric clinical trials, leading to higher cure rates and less toxicity for adolescents with ALL. 
